Treatment(s) already received-Radical prostatectomy - Page 5 of 6 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Radical prostatectomy Posts on Medivizor

How often does the urethra become blocked following prostate cancer treatment?

How often does the urethra become blocked following prostate cancer treatment?

Posted by on Sep 14, 2014 in Prostate cancer | 0 comments

In a nutshell The authors evaluated the prevalence and management of urethral blockage following certain cancer treatments. Some background Urethral stenosis is a medical condition characterized by a blockage in the urethra, the tube which drains fluid from the bladder to the outside of the body. The point of the blockage is referred to...

Read More

Is early adjuvant radiotherapy associated with different outcomes compared to delayed therapy?

Posted by on Aug 3, 2014 in Prostate cancer | 0 comments

In a nutshell The authors evaluated the optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Some background Radical  prostatectomy (surgery to remove the prostate) remains the most common treatment for localized prostate cancer (has not spread beyond the prostate)...

Read More

Will postoperative radiation decrease the likelihood of prostate cancer recurrence?

Will postoperative radiation decrease the likelihood of prostate cancer recurrence?

Posted by on Apr 12, 2014 in Prostate cancer | 0 comments

In a nutshell This study examined the safety and efficacy of radiation therapy to the prostate bed and pelvic lymph nodes following surgery for prostate cancer. Some background Postoperative radiation therapy is a standard treatment for prostate cancer patients who are at an increased risk for recurrence (return of the disease even...

Read More

Starting salvage radiotherapy early

Starting salvage radiotherapy early

Posted by on Oct 17, 2013 in Prostate cancer | 0 comments

In a nutshell This study evaluated the results of early salvage radiation therapy (ESRT) in prostate cancer patients after radical prostatectomy. Some background Following radical prostatectomy (surgical removal of the prostate gland), prostate cancer often recurs and requires further treatment. Surveillance for cancer recurrence is usually...

Read More

Risk of disease progression in prostate cancer patients with biochemical recurrence after prostatectomy

Risk of disease progression in prostate cancer patients with biochemical recurrence after prostatectomy

Posted by on May 28, 2013 in Prostate cancer | 0 comments

In a nutshell This article reviewed the long-term risks associated with biochemical recurrence (BCR) in prostate cancer (PCa) patients after prostatectomy. It also evaluated different factors that predict cancer progression and cancer-specific deaths. Some background Many PCa patients are treated with surgery to remove all or part of the...

Read More

Comparing the benefits of radiotherapy versus a “wait and see” approach for patients with stage III prostate cancer who were treated with radical prostatectomy

Posted by on May 11, 2013 in Prostate cancer | 0 comments

In a nutshell The present study evaluated whether patients with stage III prostate cancer (PCa) who underwent radical prostatectomy (RP) would benefit from further radiotherapy (RT), as opposed to the "wait and see" approach. There was a 21% increase in survival with no cancer progression in patients who received additional RT.  Some...

Read More

Evaluating the toxicity of a new immune-based treatment for advanced prostate cancer – a clinical trial

Evaluating the toxicity of a new immune-based treatment for advanced prostate cancer – a clinical trial

Posted by on Feb 25, 2013 in Prostate cancer | 0 comments

The present clinical trial evaluated the safety of an immune-based therapy (termed ‘combined immunotherapy’) as an alternative to chemotherapy for the treatment of metastatic (spread with distant metastases) prostate cancer non-responsive to hormonal treatment, or ‘castration-resistant prostate cancer’ (mCRPC). The trial aimed...

Read More

Denosumab: decrease in spread of bone cancer in men with prostate cancer (not responsive to hormone therapy & surgery)

Denosumab: decrease in spread of bone cancer in men with prostate cancer (not responsive to hormone therapy & surgery)

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study assessed the efficiency of a drug named Denosumab in delaying the spread of prostate cancer to the bone in men with resistant prostate cancer (not responding to hormone therapy and surgery). The results show that the drug tested delayed bone involvement by few months.  Some background Bone metastases are...

Read More

Treatment options for localized prostate cancer – comparing long-term adverse effects

Treatment options for localized prostate cancer – comparing long-term adverse effects

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell This study aimed to identify health-related decline in quality of life 4 to 8 years after prostate cancer (PC) treatment. Main finding: measures of quality of life vary based on therapy choice. Some background Treatments for localized PC (confined to the prostate gland) include radical prostatectomy (RP), brachytherapy (BT) and...

Read More